Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1265

Sort by

Sort Order Select

Journal Articles

YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m 6 A-dependent manner

Blood (2021) 138 (1): 71–85.

https://doi.org/10.1182/blood.2020009676

Published: 2021

Includes: Supplemental data

Journal Articles

Sensitive, rapid diagnostic test for transient abnormal myelopoiesis and myeloid leukemia of Down syndrome

David Cruz Hernandez, Marlen Metzner, Anne Pieta de Groot, Batchimeg Usukhbayar, Natalina Elliott, Irene Roberts, Paresh Vyas

Blood (2020) 136 (12): 1460–1465.

https://doi.org/10.1182/blood.2020005610

Published: 2020

Includes: Supplemental data

Journal Articles

Reduced–dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study

Francisco Pedrosa, Elaine Coustan-Smith, Yinmei Zhou, Cheng Cheng, Arli Pedrosa, Mecneide Mendes Lins, Marcia Pedrosa, Norma Lucena-Silva, Alessandra Maria de Luna Ramos, Ester Vinhas, Gaston K. Rivera, Dario Campana, Raul C. Ribeiro

Blood (2020) 135 (17): 1458–1466.

https://doi.org/10.1182/blood.2019004215

Published: 2020

Includes: Supplemental data

Journal Articles

Myeloid cell–targeted miR-146a mimic inhibits NF-κB–driven inflammation and leukemia progression in vivo

Yu-Lin Su, Xiuli Wang, Mati Mann, Tomasz P. Adamus, Dongfang Wang, Dayson F. Moreira, Zhuoran Zhang, Ching Ouyang, Xin He, Bin Zhang, Piotr M. Swiderski, Stephen J. Forman, David Baltimore, Ling Li, Guido Marcucci, Mark P. Boldin, Marcin Kortylewski

Blood (2020) 135 (3): 167–180.

https://doi.org/10.1182/blood.2019002045

Published: 2020

Includes: Supplemental data

Journal Articles

Coactivation of NF-κB and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion

Blood (2020) 135 (2): 108–120.

https://doi.org/10.1182/blood.2019001438

Published: 2020

Includes: Supplemental data

Journal Articles

Integrated Transcriptomic and Genomic Sequencing Identifies Prognostic Constellations of Driver Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Ilaria Iacobucci, PhD, Manja Meggendorfer, PhD, Niroshan Nadarajah, Stanley Pounds, PhD, Lei Shi, PhD, Chunxu Qu, PhD, Constance Baer, PhD, Claudia Haferlach, MD, Wolfgang Kern, MD, Charles G. Mullighan, MBBS, MD, Torsten Haferlach, MD

Blood (2019) 134 (Supplement_2): LBA-4.

https://doi.org/10.1182/blood-2019-132746

Published: 2019

Journal Articles

Pharmacological Inhibition of the RNA m 6 a Writer METTL3 As a Novel Therapeutic Strategy for Acute Myeloid Leukemia

Konstantinos Tzelepis, Etienne De Braekeleer, PhD MSc, Eliza Yankova, PhD, Justyna Rak, PhD, Demetrios Aspris, MSc, Ana Filipa Domingues, PhD, Richard Fosbeary, Alan Hendrick, PhD, Dan Leggate, PhD, Yaara Ofir-Rosenfeld, PhD, Alexandra Sapetschnig, PhD, Cristina Pina, MDDPhil, Mark Albertella, PhD, Wesley Blackaby, PhD, Oliver Rausch, PhD, George S. Vassiliou, FRCPath, MRCP, PhD, Tony Kouzarides, PhD

Blood (2019) 134 (Supplement_1): 403.

https://doi.org/10.1182/blood-2019-127962

Published: 2019

Journal Articles

Spliceosomal Disruption of the Non-Canonical SWI/SNF Chromatin Remodeling Complex in SF3B1 Mutant Leukemias

Daichi Inoue, MD PhD, Chew Guo-Liang, Bo Liu, PhD, Stanley C Lee, PhD, Brittany C Michel, Joey Pangallo, B.S., Andrew R D'Avino, Khrystyna North, Lillian E Bitner, BSc, Muran Xiao, Susumu Kobayashi, Akihide Yoshimi, MD PhD, Hana Cho, MSc, Sydney X Lu, MD PhD, Justin Taylor, MD, Cigall Kadoch, PhD, Robert K. Bradley, PhD, Omar Abdel-Wahab, MD

Blood (2019) 134 (Supplement_1): 637.

https://doi.org/10.1182/blood-2019-124616

Published: 2019

Journal Articles

Human CD83 Targeted Chimeric Antigen Receptor T Cell for the Prevention of Graft Versus Host Disease and Treatment of Myeloid Leukemia

Bishwas Shrestha, PhD, Kelly Walton, Jordan Reff, Elizabeth M. Sagatys, MD, Nhan Tu, PhD, Justin C. Boucher, PhD, Tayyeb Ghafoor, BS, Joseph Pidala, MD, Bruce R. Blazar, MD, Claudio Anasetti, MD, Brian C. Betts, MD, Marco L. Davila, MD PhD

Blood (2019) 134 (Supplement_1): 196.

https://doi.org/10.1182/blood-2019-124031

Published: 2019

Journal Articles

High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction

Johann K. Hitzler, MD, Jason Berman, MD, Robert B. Gerbing, Amy Beckman, Betsy A Hirsch, PhD, Susana C. Raimondi, PhD, Todd E Druley, MD PhD, Michael R. Loken, PhD, Lisa Eidenschink Brodersen, PhD, Karen Chisholm, Shelton A. Viola, MD, Jeffrey W. Taub, MD, Alan S Gamis, MD MPH, Todd A. Alonzo, PhD, E. Anders Kolb, MD

Blood (2019) 134 (Supplement_1): 118.

https://doi.org/10.1182/blood-2019-126723

Published: 2019

Journal Articles

Combination of Tigecycline and Homoharringtonine Synergistically Enhances Anti-Leukemia and Anti-MDS Effect Followed By Inhibiting Mitochondrial Translation through AKT/Mtorpathway and Downregulation of Anti-Apoptotic Proteins

Jie Jin, MD PhD, Hongyan Tong, Yang Haiyang

Blood (2019) 134 (Supplement_1): 5387.

https://doi.org/10.1182/blood-2019-128171

Published: 2019

Journal Articles

Unexpected Concomitance of BCR-ABL and PML-Rarα Leukemia - Three-Year Follow-up

Caique Pereira de Moura Martins, MDcal Student, João Vítor Ternes Rech, MDcal Student, Lee I-Ching, MD, Giovanna Steffenello Durigon, MD, Joanita Angela Del Moral, MD, Mirella Rodrigues Oliveira, MD, Bruno Vieira Dias, Maria Claudia Santos, PhD, Andressa Oliveira Martin Wagner, André Guedes Vieira

Blood (2019) 134 (Supplement_1): 5038.

https://doi.org/10.1182/blood-2019-132259

Published: 2019

Journal Articles

This Is a Title in Title Case: A Combination of Low-Dose Decitabine and Chidamide Resulted in Synergistic Effects on the Proliferation and Apoptosis of Human Myeloid Leukemia Cell Lines

Fangfang Xu, PhD, Honggang Guo, MD, Mingyue Shi, MD, Siwei Liu, MD, Min Wei, MD, Kai Sun, MD, Yuqing Chen, MD

Blood (2019) 134 (Supplement_1): 5160.

https://doi.org/10.1182/blood-2019-128663

Published: 2019

Journal Articles

Changes in the Multipotent Stromal Mesenchymal Cells from the Bone Marrow of the Patients with Hematological Diseases in Debut and after the Treatment

Irina N. Shipounova, PhD, Nataliya A. Petinati, MD PhD, Nina J. Drize, PhD, Aminat A. Magomedova, MD PhD, Ekaterina A. Fastova, MD, Sergey K. Kravchenko, MD PhD, Ekaterina Yu. Chelysheva, MD PhD, Oleg A. Shukhov, MD PhD, Anna G. Turkina, Prof., MD, Elena N. Parovichnikova, MD PhD, Valery G. Savchenko, MD PhD academician

Blood (2019) 134 (Supplement_1): 5014.

https://doi.org/10.1182/blood-2019-123396

Published: 2019

Journal Articles

Phase I Study of Pracinostat in Combination with Gemtuzumab Ozogamicin (PraGO) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Talha Badar, MD, Guru Subramanian Guru Murthy, MD, Lyndsey Runaas, MD, Karen-Sue B. Carlson, MD PhD, Laura C. Michaelis, MD, Alexandra M. Harrington, MDMT(ASCP), Ehab L. Atallah, MD, Sameem Abedin, MD

Blood (2019) 134 (Supplement_1): 5068.

https://doi.org/10.1182/blood-2019-123237

Published: 2019

Journal Articles

Mapping Stem Cell Dependencies in Cancer Heterogeneity and Therapy Resistance

Tannishtha Reya, PhD

Blood (2019) 134 (Supplement_1): SCI-3.

https://doi.org/10.1182/blood-2019-121051

Published: 2019

Journal Articles

Financial Impact of Imatinib Discontinuation in Brazil - a Pharmoeconomic Study

Renato Torrescasana Centrone, Isabel Bonafe, Eliana C Miranda, PhD, Fernanda S Seguro, MD, Gustavo HR Magalhaes, MD MSc, Nelma D Clementino, MD, Arthur Moellmann-Coelho, MD, Ingrid Luise, MD, Monika Conchon, MD, Natália N Gonçalves, MD, Jaisson Bortolini, MD, Laura Maria Fogliatto, MD PhD, Carmino Antonio Souza, MD PhD, Katia B Pagnano, MD PhD, Israel Bendit, MD PhD

Blood (2019) 134 (Supplement_1): 5844.

https://doi.org/10.1182/blood-2019-127530

Published: 2019

Journal Articles

Characterizing Inclusion and Exclusion Criteria in Clinical Trials for CAR-T Cellular Therapy Among Adults with Hematologic Malignancies

Jordon Jaggers, Heidi D. Klepin, MD, Tanya M. Wildes, MD, Rebecca L. Olin, MD, Andrew S. Artz, MD, Sarah A Wall, MD, Samantha Jaglowski, MDMPH, Basem M. William, MRCP,MD, Don M. Benson, Jr., MD PhD, Ashley E. Rosko, MD

Blood (2019) 134 (Supplement_1): 5819.

https://doi.org/10.1182/blood-2019-131504

Published: 2019

Journal Articles

Synthetic Lethality-Based Approach Identified EED and BRD4 As Critical Survival Factorsin Acte Myeloid Leukemia with Monosomy 7

Kensuke Matsuda, MD, Yuki Kagoya, MD PhD, Sho Yamazaki, MD PhD, Masashi Miyauchi, MD PhD, Mineo Kurokawa, MD PhD

Blood (2019) 134 (Supplement_1): 1233.

https://doi.org/10.1182/blood-2019-123595

Published: 2019

Journal Articles

Mir-29 Maintains the Acute Myeloid Leukemia Epigenome By Regulating CBX2

Caryn J. Ha, BA, Wenhuo Hu, PhD, Harold K. Elias, MD, Sohini Chakraborty, PhD, Christopher Y. Park, MD PhD

Blood (2019) 134 (Supplement_1): 1236.

https://doi.org/10.1182/blood-2019-131518

Published: 2019

NARROW

YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m 6 A-dependent manner

Sensitive, rapid diagnostic test for transient abnormal myelopoiesis and myeloid leukemia of Down syndrome

Reduced–dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study

Myeloid cell–targeted miR-146a mimic inhibits NF-κB–driven inflammation and leukemia progression in vivo

Coactivation of NF-κB and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion

Integrated Transcriptomic and Genomic Sequencing Identifies Prognostic Constellations of Driver Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Pharmacological Inhibition of the RNA m 6 a Writer METTL3 As a Novel Therapeutic Strategy for Acute Myeloid Leukemia

Spliceosomal Disruption of the Non-Canonical SWI/SNF Chromatin Remodeling Complex in SF3B1 Mutant Leukemias

Human CD83 Targeted Chimeric Antigen Receptor T Cell for the Prevention of Graft Versus Host Disease and Treatment of Myeloid Leukemia

High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction

Combination of Tigecycline and Homoharringtonine Synergistically Enhances Anti-Leukemia and Anti-MDS Effect Followed By Inhibiting Mitochondrial Translation through AKT/Mtorpathway and Downregulation of Anti-Apoptotic Proteins

Unexpected Concomitance of BCR-ABL and PML-Rarα Leukemia - Three-Year Follow-up

This Is a Title in Title Case: A Combination of Low-Dose Decitabine and Chidamide Resulted in Synergistic Effects on the Proliferation and Apoptosis of Human Myeloid Leukemia Cell Lines

Changes in the Multipotent Stromal Mesenchymal Cells from the Bone Marrow of the Patients with Hematological Diseases in Debut and after the Treatment

Phase I Study of Pracinostat in Combination with Gemtuzumab Ozogamicin (PraGO) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Mapping Stem Cell Dependencies in Cancer Heterogeneity and Therapy Resistance

Financial Impact of Imatinib Discontinuation in Brazil - a Pharmoeconomic Study

Characterizing Inclusion and Exclusion Criteria in Clinical Trials for CAR-T Cellular Therapy Among Adults with Hematologic Malignancies

Synthetic Lethality-Based Approach Identified EED and BRD4 As Critical Survival Factorsin Acte Myeloid Leukemia with Monosomy 7

Mir-29 Maintains the Acute Myeloid Leukemia Epigenome By Regulating CBX2

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only